Top Markets
#1 CyberDEX CyberDEX +391.94%
#2 OVERTAKE OVERTAKE +60.20%
#3 deBridge deBridge +25.79%
#4 Clearpool Clearpool +25.70%
#5 Playnance Playnance +23.95%
#6 Nillion Nillion +21.37%
#7 B3 (Base) B3 (Base) +19.47%
#8 AUKI AUKI +15.74%
#9 龙虾 (Lobster) 龙虾 (Lobster) +15.62%
#10 Codatta Codatta +15.06%
Coin of the day
CyberDEX CyberDEX
Settings
Language
ENGLISH
Currency
USD
Theme
Nuformix plc Nuformix plc

Nuformix plc

NFX
Rank in Stocks #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
Share Price
$0.00185055
Market Cap
$48.29K
Change (1 day)
-3.55%
Change (1 year)
30.31%
Country
GB
Trade Nuformix plc (NFX)

Category

Healthcare
Revenue for Nuformix plc (NFX)
Revenue in Mar 2026 TTM: 0.00
According to Nuformix plc latest financial reports the company's current revenue (TTM) is 0.00. In 2024 the company made a revenue of 0.00 equal to the revenue in the year 2023 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Nuformix plc from 2014 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 $65.73K -75.61%
2021 $269.56K -59.39%
2020 $663.79K -16.44%
2019 $794.35K 3,678.32%
2018 $21.02K 0.00%
2017 0.00 -100.00%
2016 $872.91K 181.15%
2014 $310.47K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH